Screener
Collegium Pharmaceutical, Inc. COLL Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Product revenues, net by Product | ||||||
| Azstarys | $12.91M— | —— | —— | —— | $0— | |
| Belbuca | $57.67M+9.6% | $52.65M+1.9% | $59.14M+7.1% | $58.26M+9.5% | $52.6M+0.8% | |
| Jornay PM | $46.06M+41.2% | $38.89M+36.3% | $45.89M+56.7% | $41.8M+425% | $32.63M— | |
| Nucynta ER AG | $2.78M— | $1.45M— | —— | —— | $0— | |
| Nucynta ER | $15.72M-21.2% | $18.23M-7.4% | $18.54M+5.7% | $22.81M+15.4% | $19.95M+3.5% | |
| Nucynta IR AG | $2.36M— | $1.26M— | —— | —— | $0— | |
| Nucynta IR | $14.36M-45.8% | $26.08M-4.9% | $29.41M+21.4% | $31.99M+26.1% | $26.5M+5.2% | |
| Symproic | $3.02M-18.9% | $4.19M+49.0% | —— | $4.03M+14.4% | $3.72M-7.7% | |
| Xtampza ER | $45.01M-14.4% | $50.77M+6.6% | —— | —— | $52.61M+10.0% |
FAQ
- How does Collegium Pharmaceutical, Inc. break its business down?
- Collegium Pharmaceutical, Inc. (COLL) reports product revenues, net by product across 10 parts — Azstarys, Belbuca, Jornay PM, Nucynta ER AG and Nucynta ER. Each is extracted from the segment footnotes and tracked over time.
- Where does Collegium Pharmaceutical, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Collegium Pharmaceutical, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
